HIV combo therapy suppresses HBV in some patients

04/29/2013 | MedPage Today (free registration)

Tenofovir and emtricitabine can suppress hepatitis B among patients in the immune-tolerant stage, according to a study presented at a liver disease research meeting in Europe. Researchers tracked 126 HBV patients and found that 76% of those who took the tenofovir-emtricitabine combination for four years experienced viral suppression compared with 55% of those who received tenofovir alone. Few patients, however, regained their immune response to the pathogen, and among participants who stopped taking the drugs, viral loads returned to pre-study levels.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC